Skip to content

Evaluation of the Accuracy of the Elastic Fusion MRI-ultrasound Obtained in Vivo by the Koelis™ System

Evaluation of the Accuracy of the Elastic Fusion MRI-ultrasound ((Magnetic Resonance Imaging) Obtained in Vivo by the Koelis™ System

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02879851
Acronym
EFEL
Enrollment
30
Registered
2016-08-26
Start date
2015-01-31
Completion date
Unknown
Last updated
2016-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of the Prostate

Keywords

ultrasound, Koelis system, MRI, gold grain

Brief summary

The study aims at quantifying the registration error obtained in routine patients in different parts of the prostate and for operators with different experience in order to assess the average precision of the elastic MR-ultrasound fusion obtained by Koelis™ system. Patients referred for placement of intraprostatic fiducials before radiotherapy for prostate cancer will be prospectively offered to enter the study. The fiducials will be placed under transrectal ultrasound guidance, in the prostate apex, midgland and base, according to our routine procedure. A 3D Ultrasound acquisition of the prostate will be obtained at the end of the placement. As per our routine procedure, patients will undergo unenhanced prostate MRI to control the position of the fiducials. An elastic fusion of the MR images and the 3D ultrasound acquisitions will be retrospectively performed by operators of varying experience using the Koelis system. The fiducials (visible on MR and ultrasound images) will be used to quantify the registration error.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Patient requiring placement of intraprostatic fiducials * No contra-indication for fiducials placement * No contra -indication to MRI * No contra -indication for intravenous injection of gadolinium chelates * Patient affiliated to the social security system * Patients who received oral and written information

Exclusion criteria

* Patient deprived of liberty as a result of a judicial or administrative decision. * Patient under guardianship or curatorship. * Any event preventing or prematurely interrupting the collection of assessment criteria would result in the premature exit of the subject.

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of the overall registration obtained by the Koelis™ system1 monthThe fusion will be performed retrospectively without interfering with patient management. This fusion is an off-line analysis that will be performed within one month of the images acquisition. Each of the four operators will perform a US/MR fusion for all patients and will be blinded to the fusions performed by the others. The results will be presented when all operators have finished the fusions in all patients. The overall registration error (TRE3D, defined as the Euclidean distance between the US marker and the MR marker after fusion) will be calculated based on the 3D coordinates of the fiducials on MR and ultrasound images.

Secondary

MeasureTime frameDescription
Influence on TRE3D of the position of the fiducials (apex, midgland and base)1 monthThe fusion will be performed retrospectively without interfering with patient management. This fusion is an off-line analysis that will be performed within one month of the images acquisition. Each of the four operators will perform a US/MR fusion for all patients and will be blinded to the fusions performed by the others. The results will be presented when all operators have finished the fusions in all patients. The distribution of TRE3D for the markers at the apex, midgalnd and base will be compared
Influence on TRE3D of the experience of the fusion operators1 monthThe fusion will be performed retrospectively without interfering with patient management. This fusion is an off-line analysis that will be performed within one month of the images acquisition. Each of the four operators will perform a US/MR fusion for all patients and will be blinded to the fusions performed by the others. The results will be presented when all operators have finished the fusions in all patients. The distribution of TRE3D for the four operators will be compared

Countries

France

Contacts

Primary ContactOlivier ROUVIERE, Professor
olivier.rouviere@chu-lyon.fr+334 72 11 09 50

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026